Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 78

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 78
---
 period in
2022, an increase of $0.1 million. The increase was primarily due to recognition of higher investment tax credits offset by foreign exchange
loss.

Net
loss

For
the three-month period ended December 31, 2024, we reported a consolidated net loss of $6.7 million, or $2.15 loss per common share,
as compared with a consolidated net loss of $1.6 million, or $0.85 loss per common share for the same period in 2023. The $5.1 million
increase in net loss is attributable to:

  an                                                                                              
  an                                                                                              
  a                                                                                               
  a                                                                                               
  a                                                                                               
  an                                                                                              

For
the twelve-month period ended December 31, 2024, we reported a consolidated net loss of $15.3 million, or $5.93 loss per common share,
as compared with a consolidated net loss of $3.5 million, or $1.89 loss per common share for the same period in 2023. The $11.8 million
increase in net loss is attributable to:

  an                                                                                             
  an                                                                                             
  a                                                                                              
  a                                                                                              
  a                                                                                              
  an                                                                                             

For
the twelve-month period ended December 31, 2023, we reported a consolidated net loss of $3.5 million, or $1.89 loss per common share,
as compared with a consolidated net income of $3.5 million, or $1.87 income per common share for the same period in 2022. The $7.0 million
increase in net loss is attributable to:

  a                                                                                              
  an                                                                                             
  an                                                                                             
  a                                                                                              

  57  

Selected
quarterly financial data

                                                               Three months ended                                                                           
  (in thousands of US dollars, except for per share data)      December                            September                  June                          
                                                               31,                                 30,                        30,                           
                                                                                                                                                            
                                                               2024                                2024                       2024                          
                                                               $                                   $                          $                             
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Revenues                                                                              3,322                      1,871                 2,337       2,057  
  Net loss                                                                             (6,731                     (5,755                (1,422      (1,401  
  Net loss per share (basic